CTLA4 and breast carcinoma: Recent research from clinical trials has demonstrated that a single dose of anti-CTLA-4 monoclonal antibody (ipilimumab) leads to increased intratumor T cell density [11], which is associated with a lower risk of chemotherapy resistance and higher overall survival in breast cancer patients [12,13].